India vs Tajikistan: Average cost of multi drug-resistant tuberculosis treatment
India
400 constant 2022 US$
in 2024
Tajikistan
257 constant 2022 US$
in 2024
India rank
87th
Tajikistan rank
90th
Average cost of multi drug-resistant tuberculosis treatment over time
- India
- Tajikistan
How they compare
India currently reports 400 constant 2022 US$ against 257 constant 2022 US$ in Tajikistan, a difference of 143 constant 2022 US$.
That makes India's figure about 1.6 times Tajikistan's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Tajikistan ahead.
India ranks 87th and Tajikistan ranks 90th of 92 countries.
Tajikistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,700 constant 2022 US$ | 2,726 constant 2022 US$ | 1,026 constant 2022 US$ | Tajikistan |
| 2020s | 444.2 constant 2022 US$ | 1,817 constant 2022 US$ | 1,373 constant 2022 US$ | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, India or Tajikistan?
- India, at 400 constant 2022 US$ against 257 constant 2022 US$ in Tajikistan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between India and Tajikistan?
- 143 constant 2022 US$, with India ahead.
- How many years of comparable data are there for India and Tajikistan?
- 8 years are reported by both, from 2017 to 2024.
- How do India and Tajikistan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- India ranks 87th and Tajikistan ranks 90th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.